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Abstract
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation and joint
structural deterioration. Driven by recent expectations that patients in clinical trials randomized to placebo should
be ‘rescued’ with active therapy within 6 months of starting treatment, the relative benefit of arresting joint
damage with biologic agents beyond this period is unclear. With longer-term evidence of the rate of joint
deterioration with minimal treatment, the efficacy of biologic agents and novel treatments might be projected beyond
the placebo-controlled phase observed in clinical trials. The aim of this study was to estimate radiographic structural
deterioration over time in patients with moderate-to-severe RA minimally treated with DMARDs.
Methods: A literature review identified evidence of joint structural deterioration in patients with (DMARD-IR
population) and without (non-DMARD-IR population) a history of inadequate response to DMARDs. Patients
were minimally treated with one non-biologic DMARD or palliative care (non-DMARD-IR population only).
Outcomes of interest were the (modified) Total Sharp Score (TSS) and subscales (Erosion Subscore [ES] and
Joint Space Narrowing [JSN] Subscore), and Larsen score. Pooled joint-deterioration curves over time were
obtained with meta-analysis models.
Results: Mean change from baseline in TSS increased in the DMARD-IR population from 1.14 (95 % credible
interval [CrI] 0.66, 1.67) to 9.84 (5.68, 14.46) at Weeks 12 and 104, respectively, and a non-linear increase of
1.56 (0.79, 2.34) and 5.13 (−1.35, 11.67) in the non-DMARD-IR population. At the same time points, mean changes
(95 % CrI) were 0.51 (0.27, 0.83) and 4.43 (2.38, 7.21) for ES and 0.36 (0.09, 0.67) and 3.14 (0.80, 5.78) for JSN in the
DMARD-IR population, whereas corresponding changes in the non-DMARD-IR population were 0.69 (0.31, 1.12) and
2.93 (0.92, 5.02), and 0.29 (0.17, 0.44) and 2.55 (1.45, 3.80), respectively. Larsen scores were only available
for the non-DMARD-IR population, with mean changes (95 % CrI) of 0.08 (0.04, 0.11) and 0.65 (0.36, 0.96)
at Weeks 12 and 104, respectively.
Conclusion: Minimal treatment of RA with one non-biologic DMARD results in deterioration of joint structure
in patients with or without a history of inadequate response to non-biologic DMARDs.
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Background
Rheumatoid arthritis (RA) is a common chronic inflam-
matory joint disorder. Without treatment most patients
with RA become severely disabled. The goals of RA
treatment are to reduce disease activity, reduce or inhibit
the rate of joint damage and, if possible, achieve remission.
Current pharmacologic therapies include traditional
disease-modifying anti-rheumatic drugs (DMARDs) and
biologic agents [1–3].
Biologic agents have been shown to inhibit radio-
graphic joint destruction in patients with an inadequate
response to non-biologic DMARDs. Driven by recent
expectations that patients in clinical trials randomized to
placebo should be ‘rescued’ with active therapy within
6 months of starting treatment, the relative benefit of
arresting joint damage with biologic agents beyond this
period is unclear. With longer-term evidence of the rate
of joint deterioration with placebo or minimal treatment,
the efficacy of biologic agents and novel treatments
might be projected beyond the placebo-controlled phase
observed in clinical trials.
The objective of the current study was to estimate
radiographic joint destruction over time with minimal
treatment among the following populations of biologic
DMARD-naïve RA patients: (1) moderate-to-severe RA
patients with a history of inadequate response to non-
biologic DMARDs who were treated with one (other)
non-biologic DMARD; and (2) moderate-to-severe RA
patients without a history of inadequate response to a
DMARD, who received palliative care (non-steroidal
anti-inflammatory drugs [NSAIDs], analgesics, low-dose
glucocorticoids) or were being minimally treated with
one non-biologic DMARD. The first population was
termed the “DMARD-IR population” and the second
population the “non-DMARD-IR population”. The
evidence for this analysis was obtained by means of a
systematic literature review.
Methods
Study identification and selection
A systematic literature search was performed to identify
studies that provided information concerning joint
structural deterioration among minimally treated RA
patients. MEDLINE® and EMBASE® databases were
searched simultaneously for articles published in English,
French, or German, from 1970 to October 2009, with a
predefined search strategy. Search terms included a
combination of free text and thesaurus terms related to
RA, NSAIDs, glucocorticoids, non-biologic DMARDs,
clinical trials, and observational studies. (See Additional
file 1 for details of the search strategy.) The relevance of
each citation identified from the databases was based on
the title and abstract according to the predefined selec-
tion criteria outlined below:
Populations of interest
DMARD-IR, i.e., adult RA patients naïve to biologic
DMARDs with a history of inadequate response to one
or more non-biologic DMARDs; and non-DMARD-IR,
i.e., adult RA patients naïve to biologic DMARDs with-
out a history of inadequate response to a non-biologic
DMARD. The non-DMARD-IR population could
include both non-biologic DMARD-naïve (completely
DMARD-naïve) and non-naïve (non-biologic DMARD-
experienced) patients.
Interventions
NSAIDs, glucocorticoids, and single non-biologic
DMARDs, including methotrexate (MTX), azathioprine
(AZA), sulfasalazine (SSZ), leflunomide (LEF), ciclos-
porin A (CSA), hydroxychloroquine (HCQ), minocy-
cline, D-penicillamine, and gold salts.
Outcomes
Radiographic measures of joint deterioration: Larsen score
(0–200 points range) [4, 5] and Total Sharp Score (TSS)
(0–448), plus two TSS subscores (Erosion Subscore [ES]
(0–280) and Joint Space Narrowing [JSN] (0–168) Sub-
score) [6–10].
Study design
Randomized controlled trials (RCTs), and prospective
and retrospective observational cohort studies. Only
study arms concerning the interventions of interest were
included.
Publications were obtained, if available, for any ab-
stracts that potentially met the selection criteria. Based
on these full-text reports, two reviewers evaluated
whether each study met the selection criteria and any
disagreements were resolved in a consensus meeting.
Data extraction
For each of the selected studies that reported sufficient
follow-up data, details were extracted from the relevant
study arms on study design, population characteristics,
interventions, and the outcomes of interest, i.e., the
(modified) TSS and its two subscores (ES and JSN). Data
were extracted into a study database according to the
Preferred Reporting Items for Systematic Reviews and
Meta-analyses (PRISMA) 2009 [11]. Mean change from
baseline (CFB) in the outcomes of interest was extracted
from tables, text, or graphs. If not reported, CFBs were
calculated as the difference between reported follow-up
and baseline values. Corresponding standard errors were
extracted directly or calculated indirectly based on the
following data (if available): reported standard devi-
ation (SD) with sample size, 95 % confidence interval,
or p-values (in this order of preference).
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Larsen scores were not consistently evaluated or
reported. Different numbers and sets of joints were eval-
uated in the various studies, including hands and feet, or
hands, feet, and wrists, and many studies did not report
which or how many joints were evaluated. Moreover,
some studies reported the total scores and some
reported an average of scores per joint. Consequently,
the analyses were based on standardized mean CFB in
Larsen score, calculated as the reported CFB divided by
the corresponding SD of this change.
Meta-analysis of joint structural deterioration over time
Mean CFB in TSS, ES, JSN, and the standardized Larsen
scores obtained from the selected studies were combined
with Bayesian random-effects meta-analysis models to
estimate joint deterioration over time for the DMARD-
IR and non-DMARD-IR populations [12]. Any study
that did not explicitly state whether or not patients had
previously shown an inadequate response to DMARDs
was assigned to the non-DMARD-IR population.
Depending on the availability of data by endpoint and
population, two sets of analyses were performed. In the
first series of analyses, all non-biologic-DMARDs were
considered as one group and the development of the
outcomes of interest was estimated. Studies evaluating
only NSAIDs were not combined with studies evaluating
DMARDs. In the second series of analyses, the develop-
ment of the outcome over time was compared among
individual DMARD (e.g., MTX, LEF, and AZA) using
only data from comparative studies. All analyses pro-
vided curves reflecting the pooled mean CFB in TSS, ES,
JSN, and the standardized Larsen score over time, along
with their respective 95 % credible intervals (95 % CrIs).
Within the Bayesian framework, analyses consisted of
data, likelihood, parameters, and a model. Bayesian
methods involve a formal combination of a prior prob-
ability distribution (that reflects a prior belief of the pos-
sible values of the parameters of interest) with a
likelihood distribution based on the observed data, to
obtain a posterior probability distribution of the parame-
ters of interest [13]. A normal likelihood distribution
was assumed.
We opted for statistical models that assume that out-
comes develop over time in a linear fashion, as well as
models that anticipate that outcomes can develop in a
non-linear fashion over time [14–16]. The advantage of
the used meta-analysis models is that all available data
points of each study included in the analysis are cap-
tured, even if time points are not the same across stud-
ies, and (non-) linear trends of the development of
outcomes over time are estimated [12]. Details of the
meta-analysis models are provided in Additional file 2.
Model 1 and 2 were used to estimate the development
over time where all non-biologic DMARDs were
grouped. Model 3 and 4 were used for the comparative
analysis of different DMARDS. The deviance informa-
tion criterion (DIC) provides a measure of model fit that
penalizes model complexity and was used to compare
the different models [17, 18]. The model with the lowest
DIC and, therefore the model with the “best fit”, was
considered the most appropriate.
To avoid prior beliefs influencing the results of the
model, non-informative prior distributions were used.
Prior distributions of all model parameters were normal
distributions with a mean of 0 and a variance of 104,
except for heterogeneity, which was a uniform distribu-
tion with a range of 0–10. With such a “flat” prior, it is
assumed that, in advance of the actual data, any par-
ameter value is “equally” likely. As a consequence,
posterior results are not influenced by the prior dis-
tribution but are driven by the data. The result of the
Bayesian analysis is a (joint) posterior distribution for
the model parameters of interest. The model parame-
ters were estimated using a Markov chain Monte




The study selection process, including the reasons for
exclusion, is summarized in Fig. 1. The literature
search identified 2076 potentially relevant studies, al-
though the first review excluded 1892 (91 %) of these.
The full-text review of the 184 remaining studies ex-
cluded another 111 studies. Of the 73 articles meeting
the selection criteria, another 29 studies were ex-
cluded because of insufficient data on the outcomes
of interest during follow-up. Overall, 44 studies were
included [20–63].
Study characteristics
Information on key study and patient characteristics are
presented in Tables 1 and 2. All 44 studies were RCTs,
except for one retrospective [31] and two prospective
cohort studies [33, 52], and were published between
1982 and 2009, with follow-up periods ranging from
24 weeks to 2 years. Twelve studies concerned the
DMARD-IR population [20–31] and the remaining 32
studies concerned the non-DMARD-IR population
[32–63]. Only two studies provided data on the Lar-
sen score for the DMARD-IR population, while 10
provided data on the (modified) TSS in this popula-
tion. For the non-DMARD-IR population, 17 studies
provided data on Larsen score only, 14 studies pro-
vided data on the (modified) TSS, and one study
provided data on both. As some of the studies con-
tributed data from more than one arm (three studies
in the DMARD-IR population [21, 22, 31] and 13
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studies in the non-DMARD-IR population [35, 36, 38,
41, 48, 50, 51, 54, 57, 59, 61–63]), the total number
of treatment arms included in the analyses was 63: 16
for DMARD-IR and 47 for non-DMARD-IR. Among
the 47 arms that formed the non-DMARD-IR popula-
tion, only 12 included patients who had been previ-
ously exposed to DMARDs. Hence, the majority of
patients in this population could be considered
DMARD-naïve.
The patients received the following treatments g :
MTX (in 12 treatment arms across the studies); AZA
(2); SSZ (1); and gold salts (1) for the DMARD-IR
population; and MTX (16); gold salts (9); SSZ (5);
LEF (four 4); CSA (4); HCQ (1); D-penicillamine (1);
antimalarials, D-penicillamine, SSZ, or gold salts (2);
any one of a list of non-biologic DMARDs (4); and
NSAIDs (4) for the non-DMARD-IR population. The
number of patients included ranged from 29 to 228
for DMARD-IR arms and from 20 to 501 for non-
DMARD-IR arms.
Patient characteristics
The DMARD-IR and the non-DMARD-IR populations
showed comparable distributions for gender, age, base-
line C-reactive protein (CRP) level, and erythrocyte sedi-
mentation rate (ESR). On average, 73 % of the patients
were women in the DMARD-IR studies versus 70 % in
the non-DMARD-IR studies; the average ages were 54
and 52 years, respectively. The median of the reported
baseline CRP level was 2.2 mg/dL across the DMARD-
IR studies and 2.6 mg/dL across the non-DMARD-IR
studies. The median of the reported baseline ESR was
43 mm/h across DMARD-IR studies and 44 mm/h
across non-DMARD-IR studies. There was a large vari-
ation in baseline CRP level and ESR across the non-
DMARD-IR studies. As expected, the disease duration
was skewed and longer among the DMARD-IR patients
(median of 88 months) versus the non-DMARD-IR
patients (median of 15 months). For the DMARD-IR
population, the median of the reported baseline Health
Assessment Questionnaire (HAQ) score across the stud-
ies was 1.7; the HAQ scale ranges from zero (no disabil-
ity) to three (completely disabled). The median baseline
TSS for the DMARD-IR population was 53. For the
non-DMARD-IR population the median of the reported
HAQ scores across studies was 1.0 and the median TSS
was 11.9.
Joint structural deterioration over time in the DMARD-IR
population
The mean CFB in TSS within the DMARD-IR popu-
lation, as obtained from the individual studies, is pre-
sented in Fig. 2. These results were combined with a
random-effects meta-analysis (Additional file 2,
Model 1), where the change in TSS over time devel-
oped in a linear fashion from 1.14 at Week 12 to
9.84 at Week 104 (Table 3). There was a high prob-
ability that continuation of treatment with any one
non-biologic DMARD in the setting of inadequate
Fig. 1 Flow diagram of study selection
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Table 1 Key study characteristics
Study [Ref] Study design Follow-up period Reassignment in
studies of biologics
Larsen JSN ES TSS Outcomes of
interest
DMARD-IR population
Breedveld et al. 2004 [20] RCT NA No reassignment; MTX dose
increase for non-responders
No No No Yes Modified TSS
Hamdy et al. 1987 [21] Double-blind RCT 1.5 years NA No No No Yes TSS
Jeurissen et al. 1991 [22] Double-blind RCT 48 weeks NA No No No Yes Modified TSS
Keystone et al. 2004 [23] Double-blind RCT 1 year No reassignment; MTX dose
increase for non-responders
No Yes Yes Yes Modified TSS
Keystone et al. 2008 [24] Double-blind RCT 1 year No reassignment No Yes Yes Yes Modified TSS
Lipsky et al. 2000 [25] RCT 1 year No reassignment No Yes Yes Yes Modified TSS
Maini et al. 2004 [26] Double-blind RCT 2 years No reassignment No Yes Yes Yes Modified TSS
Sany et al. 1990 [27] RCT 2 years NA Yes No No No Larsen scores
Smolen et al. 2009 [28] RCT 2 years No reassignment No Yes Yes Yes Modified TSS
van der Heijde et al. 2006 [29] Double-blind RCT 2 years No reassignment No Yes Yes Yes Modified TSS
van Holten et al. 2005 [30] Double-blind RCT 24 weeks NA No No No Yes Modified TSS
Wick et al. 2005 [31] Retrospective cohort NA NA Yes No No No Larsen scores
Non-DMARD-IR population
Bathon et al. 2000 [32] RCT 1 year No reassignment No Yes Yes Yes Modified TSS
Boiardi et al. 1999 [33] Prospective cohort 1 year NA Yes No No No Larsen scores
Breedveld et al. 2006 [34] Double-blind RCT 2 years No reassignment;
MTX dose increase
for non-responders
No Yes Yes Yes Modified TSS
Choy et al. 2008 [35] Double-blind RCT 2 years NA Yes No No No Larsen scores
Cohen et al. 2001 [36] Double-blind RCT 2 years NA No Yes Yes Yes Modified TSS
Cohen et al. 2008 [37] Double-blind RCT 1 year NA No Yes Yes No Modified TSS
Emery et al. 2000 [38] Double-blind RCT 2 years NA Yes No No No Larsen scores
Emery et al. 2008 [39] Double-blind RCT 1 year No reassignment No No No Yes Modified TSS
Emery et al. 2009 [40] Double-blind RCT 2 years No reassignment No Yes Yes Yes Modified TSS
Ferraccioli et al. 1996 [41] Open-label RCT 1 year NA Yes No No No Larsen scores
Ferraccioli et al. 1997 [42] Open-label RCT 1 year NA Yes No No No Larsen scores
Goldbach-Mansky et al. 2009 [43] RCT 24 weeks NA No Yes Yes Yes Modified TSS
Hannonen et al. 1993 [44] Double-blind RCT 48 weeks NA No Yes Yes Yes Modified TSS
Hetland et al. 2006 [45] Double-blind RCT 1 year NA Yes No No No Larsen scores
Hetland et al. 2008 [46] Double-blind RCT 2 years NA No Yes Yes Yes Modified TSS
Landewé et al. 2002 [47] Double-blind RCT 1 year NA No No No Yes Modified TSS
Larsen et al. 2001 [48] Double-blind RCT 24 weeks NA Yes No No No Larsen scores
Maravic et al. 1999 [49] Open-label RCT 1 year NA Yes No No Yes Larsen scores
and TSS




2 years NA Yes Yes Yes Yes Larsen scores
and TSS
Peltomaa et al. 1995 [51] RCT 1 year NA Yes No No No Larsen scores
Sanmarti et al. 2003 [52] Prospective cohort 1 year NA Yes No No No Larsen scores
Sarzi-Puttini et al. 2005 [53] RCT 1 year NA Yes No No No Larsen scores
Scott et al. 1985 [54] RCT 1 year NA Yes No No No Larsen scores
Scott et al. 1989 [55] RCT 1 year NA Yes No No No Larsen scores
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response would result in deterioration of the joint
structure over time.
Table 3 also presents the results of the analysis
(Additional file 2, Model 3) that compared joint
deterioration as observed with MTX and AZA. Con-
tinuation of treatment with AZA was associated with
greater joint deterioration than continuation of treat-
ment with MTX in this DMARD-IR population.
The progression in ES extracted from the individual
studies and the pooled results (0.51 at Week 12 and
4.43 at Week 104) obtained with the meta-analysis
(Additional file 2, Model 1) are presented in Fig. 3.
There was a 98 % to 100 % chance that ES would
deteriorate over time when DMARD-IR patients
received minimal treatment with a non-biologic
DMARD (Table 3). As inferred from the comparative
analysis, a greater rate of deterioration was expected
with AZA than with MTX.
When DMARD-IR patients were treated with MTX
alone mean changes in JSN were 0.36 at Week 12 and
3.14 at Week 104 (Fig. 4; Table 3).
For joint deterioration as measured with the Larsen
score, only two studies with sufficient data were available
for the DMARD-IR population [27, 31]. As neither study
reported repeated intermediate observations, no meta-
analysis model for change over time was estimated. At
24 weeks, a deterioration of 0.52 was observed with
MTX [27]. In the other study the deterioration varied
from 0.53 points with SSZ to 1.06 with gold salts at
52 weeks [31].
Joint structural deterioration over time in the
non-DMARD-IR population
The rate of deterioration in the non-DMARD-IR popula-
tion was not as great as for the DMARD-IR patients.
The progression of the TSS for the non-DMARD-IR
population is presented in Fig. 5 and Table 4. Individual
study results were combined with a random-effects
meta-analysis model, where the change in TSS from
baseline developed in a non-linear fashion (fractional
polynomial with p1 = p2 = 1. Additional file 2, Model 2)
and shows an increase in TSS from 1.56 at 12 weeks to
5.13 at 104 weeks. Up to at least 104 weeks, there was at
least a 94 % chance that continuing treatment with one
DMARD would result in deterioration of the joint struc-
ture in the non-DMARD-IR population (Table 4). An
analysis (Additional file 2, Model 4) comparing LEF and
MTX based on two head-to-head RCTs indicated a simi-
lar rate of deterioration with LEF and MTX [37, 59].
For ES, the individual study results were also com-
bined with a random-effects non-linear meta-analysis
model (fractional polynomial with p1 = 1 and p2 = 0.5;
Additional file 2, Model 2) and showed that ES wors-
ened over time from 0.69 at Week 12 to 2.93 at Week
104 when non-DMARD-IR patients continued to receive
one traditional DMARD (Fig. 6; Table 4). Comparative
analysis showed no difference in rate of deterioration
was expected between LEF and MTX (Additional file 2,
Model 4).
For the JSN and the Larsen scores, linear meta-
analysis models were appropriate to reflect the deterior-
ation up to 104 weeks (Fig. 7 and Table 4; Additional file
2, Model 1). One study evaluated treatment with
NSAIDs only and reported a mean standardized
change from baseline in the Larsen score of 0.01 up
to 52 weeks [54].
Discussion
In this study, the development of joint structural deteri-
oration among minimally treated patients with
moderate-to-severe RA was estimated based on cur-
rently available published data. Estimates were obtained
for two populations: a DMARD-IR population that con-
sisted of patients who showed previous inadequate
response with non-biologic DMARDs, and a non-
DMARD-IR population that consisted of both non-
Table 1 Key study characteristics (Continued)
Scott et al. 1990 [56] RCT 2 years NA Yes No No No Larsen scores
Smith et al. 1982 [57] Open-label RCT 2 years NA Yes No No No Larsen scores
St Clair et al. 2004 [58] RCT 2 years No reassignment No Yes Yes Yes Modified TSS,
Strand et al. 1999 [59] Double-blind RCT 1 year NA No Yes Yes Yes Modified TSS
Svensson et al. 2003 [60] Double-blind RCT 1.5 years NA Yes No No No Larsen scores
Svensson et al. 2005 [61] Open-label RCT 2 years NA No Yes Yes Yes Modified TSS
van Riel et al. 1986 [62] Single-blind RCT 1 year NA Yes No No No Modified Larsen
scores
Wassenberg et al. 2005 [63] Double-blind RCT 2 years NA No Yes Yes Yes Modified TSS
DMARD disease-modifying anti-rheumatic drug, DMARD-IR patient population with moderate-to-severe RA with a history of inadequate response to non-biologic
DMARDs who are currently treated with one (other) non-biologic DMARD, ES Erosion Subscore of TSS, JSN Joint Space Narrowing Subscore of TSS, MTX methotrexate,
NA not available, non-DMARD-IR patient population with moderate to severe RA without a history of inadequate response to a DMARD who are currently receiving
palliative care (non-steroidal anti-inflammatory drugs, analgesics, low-dose glucocorticoids) or are being minimally treated with one non-biologic DMARD,
RA rheumatoid arthritis, Ref reference, RCT randomized controlled trial, TSS modified Total Sharp Score
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HAQ (0–3) DAS-28 SJC TJC TSS JSN ES Larsen
DMARD-IR population
Breedveld et al. 2004 [20]
DMARD-experienced
MTX (n = 88) 78 54a NA 100.8 2.6a 42a 1.8a NA 20a 31a 52a 28a 24a NA
Hamdy et al. 1987 [21]
DMARD-experienced
AZA (n = 21) NA NA NA NA NA 44.8 NA NA 21.6 NA 53.1 NA NA NA
MTX (n = 21) NA NA NA NA NA 41.5 NA NA 22.2 NA 44.5 NA NA NA
Jeurissen et al. 1991 [22]
DMARD-experienced
AZA (n = 33) 52 56 (9) NA 112.8 (67.2) NA 60.2 (27.9) NA NA 18.7 (7.0) 23.0 (10.7) 60.5 NA NA NA
MTX (n = 31) 84 57 (10) NA 153.6 (120.0) NA 57.5 (27.9) NA NA 18.8 (7.2) 22.5 (10.1) 62.7 NA NA NA
Keystone et al. 2004 [23]
DMARD-experienced
MTX (n = 200) 73 56 (12) 89.5 130.8 (105.6) 1.8 (2.1) NA 1.5 (0.6) NA 19 (9.5) 28.1 (13.8) 66.4 (47.4) 29.2 (24.5) 37.2 (25.8) NA
Keystone et al. 2008 [24]
MTX-experienced
MTX (n = 199) 84 52 (11) 82.8 74.4 (52.8) 1.6a NA 1.7 (0.6) 7.0a 21.2 (9.7) 29.8 (13.0) NA NA NA NA
Lipsky et al. 2000 [25]
DMARD-IR
MTX (n = 88) 80 51 (12) 77.0 132.0 (96.0) 4.0 (4.2) 49.0 (25.0) 1.7 (0.6) NA 21 (12.0) 31.0 (18.0) 82.0 (77.0) NA NA NA
Maini et al. 2004 [26]
DMARD-experienced
MTX (n = 88) 78 54 NA NA 2.6 NA 1.8 NA 20.0 31.0 NA 28.3 23.5 NA
Sany et al. 1990 [27]
DMARD-experienced
MTX (n = 41) 88 54 (27–78)b 82.9 154.8 NA 62.8 (34.3) NA NA 9.1 (2.8) NA NA NA NA 83.8 (24.4)
Smolen et al. 2009 [28]
MTX-experienced
MTX (n = 127) 84 52 (12) 78.2 67.2 (46.8) 1.4 40.8 1.6 (0.6) 6.8 (0.9) 21.9 (9.7) 30.4 (13.4) 46.5 (58.6) 23.4 (27.7) 23.1 (32.1) NA
van der Heijde et al.
2006 [29]
MTX-experienced
MTX (n = 228) 76 52 NA NA 2.6 NA 1.7 NA 22.7 33.2 35.5 NA NA NA
van Holten et al. 2005 [30]
MTX-experienced
MTX (n = 73) 66 54 (12) 71.2 49.2 (28.8) NA NA NA NA NA NA NA NA NA NA
Wick et al. 2005 [31]
DMARD-experienced
MTX (n = 56) 71 NA NA 6.8 (3.9) 3.2 (4.0) 29.5 (20.3) 1.1 (0.6) 5.4 (1.1) 11 (5.6) 9.8 (6.2) NA NA NA 15.6 (9.6)
SSZ (n = 55) 56 NA NA 6.5 (3.6) 1.9 (18.0) 28.2 (23.1) 0.8 (0.5) 4.8 (1.1) 10.3 (5.8) 7.5 (6.0) NA NA NA 12.9 (9.4)
Gold (n = 19) 63 NA NA 7.0 (4.4) 1.1 (9.0) 16.3 (9.6) 0.8 (0.5) 4.1 (0.9) 4.5 (3.5) 4.6 (3.7) NA NA NA 9.6 (7.0)
Non-DMARD-IR population
Bathon et al. 2000 [32]
DMARD-experienced
MTX (n = 217) 75 49 (13) 89.0 12.0 (11.0) 3.7 (4.4) NA NA NA 24 (11.9) 30.0 (16.1) 12.9 (13.8) 5.4 (6.1) 7.5 (9.2) NA
Boiardi et al. 1999 [33]
DMARD-experienced
MTX (n = 20) 90 64 (13) 50.0 69.0 (90.0) 2.5 (2.1) 39.0 (22.0) NA NA 8.9 (3.8) NA NA NA NA 39.4 (34.6)
Breedveld et al. 2006 [34]
DMARD-naïve
MTX (n = 257) 74 52 (13) NA 9.6 (10.8) 4.0 (4.0) NA 1.5 (0.6) 6.3 (0.9) 22.1 (11.7) 32.3 (14.3) 21.9 (22.2) 8.2 (10.7) 13.6 (13.6) NA
Choy et al. 2008 [35]
Early RA; DMARD-
experienced
MTX (n = 117) 67 54 (21–89)b 66.0 2.7 (3.8) NA NA 1.5 (0.7) 5.8 (1.2) NA NA NA NA NA 7a (3–15)b













Table 2 Patient characteristics at baseline (Continued)
Cohen et al. 2001 [36]
MTX-naïve
LEF (n = 190) 73 54 NA 82.8 2.2 (2.8) 38.3 (26.0) 0.7 (0.5) NA 13.3 (6.3) 13.4 (5.6) 23.8 (38.5) 13.5 (17.2) 10.3 (25.6) NA
MTX (n = 190) 74 53 NA 78.0 2.0 (1.9) 35.9 (25.7) 0.7 (0.5) NA 13 (5.4) 14.3 (6.5) 25.1 (42.3) 14.5 (21.7) 10.6 (22.9) NA
Cohen et al. 2008 [37]
MTX-experienced
DMARD (n = 75) 83 57 (11) 78.0 116.4 (97.2) NA NA NA NA NA NA 29.9 (34.7) 13.3 (18.9) 16.6 (17.2) NA
Emery et al. 2000 [38]
DMARD-experienced
LEF (n = 501) 71 58 (10) NA 44.4 (38.4) NA NA NA NA 15.8 (6.0) 17.2 (6.8) NA NA NA 1.3 (0.5)
MTX (n = 498) 71 58 (11) NA 45.6 (42.0) NA NA NA NA 16.5 (5.9) 17.7 (6.7) NA NA NA 1.3 (0.5)
Emery et al. 2008 [39]
MTX-naïve
MTX (n = 263) 73 52 (1) NA 9.3 (0.4) 3.7 (3.4) 49.3 (24.1) 1.6 (0.7) 6.5 (1.0) 17.6 (10.0) 24.8 (14.5) NA NA NA NA
Emery et al. 2009 [40]
MTX-naïve
MTX (n = 257) 74 52 (13) 84.0 10.1 (10.7) 4.0 (4.0) NA 1.5 (0.7) 6.3 (0.9) 22.1 (11.7) 32.3 (14.3) 21.9 (22.2) 8.2 (10.7) 13.6 (13.5) NA
Ferraccioli et al. 1996 [41]
DMARD-naïve





78 51 (12) NA 15.6 (13.2) 8.5 (17.5) 47.5 (30.8) NA NA 14.7 (7.8) 23.2 (9.8) NA NA NA 23.8 (24.1)
Ferraccioli et al. 1997 [42]
DMARD-naïve









SSZ (n = 61) 87 52 (12) NA NA 2.5 (2.9) 51.0 (23.0) NA 7.0 (1.0) 22 (13.0) 33.0 (17.0) 21.4 (31.2) 13.3 8.1 (0.4) NA
Hannonen et al. 1993 [44]
DMARD-naïve
SSZ (n = 38) 61 52 (22–78)b 65.8 4.7 2.7 (3.0) 37.7 (21.3) NA NA 6.8 (3.3) NA 1.9 (0–14.0)b 1.1 (0–8.0)b 0.8 (0–6.0)b NA
Hetland et al. 2006 [45]
Early RA; DMARD-naïve
MTX (n = 80) 70 51a (39.5-62.5)c 59.0 46.8 1.9a 27a 0.9a 5.5 (1.3) 11a (6–15)c 14a (8–20)c NA NA NA 4.6 (7.4)
Hetland et al. 2008 [46]
Early RA; MTX-experienced
MTX (n = 80) NA NA NA NA 1.9a 27a 0.9a 5.7a 11a (6–15)c 14a (8–20)c 4.8 (5.9) 1.7 (3.8) 3.1 (4.1) NA
Landewé et al. 2002 [47]
DMARD-naïve
SSZ (n = 74) 53 NA 71.0 3.6 NA NA 1.4 (0.7) 6.1 (1.1) NA NA 5a (1–10)c NA NA NA
Larsen et al. 2001 [48]
DMARD-experienced
LEF (n = 133) 76 58 (11) NA 96.0 (108.0) NA NA NA NA NA NA NA NA NA 1.5 (0.7)
SSZ (n = 133) 69 59 (11) NA 84.0 (120.0) NA NA NA NA NA NA NA NA NA 1.4 (0.7)
Maravic et al. 1999 [49]
MTX-naïve
MTX (n = 29) 72 49 (15) 37.9 6.6 1.9a 36a NA NA 12a (3–27)b NA 4.4 NA NA 15.8 (15.9)
Marchesoni et al. 2002 [50]
DMARD-naïve
CSA (n = 22) NA 50 (12) NA 9.6 (6.0) 0.8 (1.1) 29.2 (17.4) 0.5 (0.5) 3.2 (1.2) 3.2 (4.0) 4.3 (5.2) NA NA NA 5.1 (7.0)
MTX (n = 27) NA 50 (12) NA 9.6 (6.0) 0.6 (1.3) 29.4 (13.2) 0.4 (0.5) 3.5 (1.0) 3.1 (4.6) 4.8 (5.7) NA NA NA 5.0 (8.8)
Peltomaa et al. 1995 [51]
DMARD-naïve
Gold (n = 70) 77 45 NA 7.7 2.7 35.0 NA NA NA NA NA NA NA 5.5 (0–22)b
SSZ (n = 58) 71 49 NA 5.8 2.8 41.0 NA NA NA NA NA NA NA 8.9 (0–34)b

















Table 2 Patient characteristics at baseline (Continued)
Sarzi-Puttini et al. 2005 [53]
DMARD-naïve
CSA (n = 36) 78 51 (10) 66.7 14.8 (8.4) 3.0 (1.8) 45.0 (20.0) 1.3 (0.6) NA 12.2 (5.6) 15.31 (6.41) NA NA NA 14.5 (10.0)
Scott et al. 1985 [54]
DMARD-naïve
DMARD (n = 56) 55 56 NA NA 4.9 56.5 NA NA NA NA NA NA NA 52.0 (27.7)
NSAID (n = 15) 60 52 NA NA 1.9 22.6 NA NA NA NA NA NA NA 41.3 (34.5)
Scott et al. 1989 [55]
DMARD-naïve
Gold (n = 49) 61 55 (3) NA 24.0 0.5 (1.1) 57.0 (7.0) NA NA NA NA NA NA NA 33.9 (9.8)




NA NA NA NA 6.0 NA NA NA NA NA NA NA NA 25.6
HCQ (n = 23) NA NA NA NA 6.2 NA NA NA NA NA NA NA NA 25.5
Smith et al. 1982 [57]
DMARD-naïve
Gold (n = 26) 69 45 80.8 90.0 NA 89.8 NA NA NA NA NA NA NA 54.2 (6.0)
Gold (n = 26) 62 46 65.4 76.8 NA 83.4 NA NA NA NA NA NA NA 47.4 (5.0)
St Clair et al. 2004 [58]
DMARD-experienced
MTX (n = 282) 75 50 (13) 71.0 10.8 (8.4) 2.6 (2.9) 43.0 (28.0) 1.5 (0.6) 6.7 (1.0) 22.0 (11.0) 34 (15.0) 11.3 (15.9) 3.0 (4.8) 8.3 (12.3) NA
Strand et al. 1999 [59]
MTX-naïve
LEF (n = 182) 73 54 (12) 64.8 84.0 (103.2) 2.1 (2.5) 38.4 (26.8) 0.8 (0.6) NA 13.7 (6.0) 15.5 (6.4) 23.1 (34.0) 14.2 (18.9) 9.0 (19.6) NA
MTX (n = 182) 75 53 (12) 59.4 78.0 1.9 (1.9) 33.8 (25.4) 0.8 (0.5) NA 13.0 (5.7) 15.8 (6.9) 22.8 (39.0) 14.7 (23.3) 8.1 (18.4) NA
Svensson et al. 2003 [60]
Early RA; DMARD-
experienced
MTX (n = 50) 58 52 62.0 9.0 5.4 49.9 1.2 NA 19.8 NA NA NA NA 7.5 (10.8)
Svensson et al. 2005 [61]
DMARD-naïve
DMARD (n = 119) 65 51 (14) 66.0 6.5 (3.5) 2.2 NA 1.0 (0.6) 5.3 (1.1) NA NA 4.1 (9.2) 2.2 (4.6) 1.9 (5) NA
DMARD (n = 131) 63 59 (13) 66.0 5.8 (2.9) 2.2 NA 1.0 (0.7) 5.4 (1.0) NA NA 4.8 (9.6) 2.9 (6.4) 1.9 (4) NA
Van Riel et al. 1986 [62]
DMARD-naïve
Gold (n = 22) 77 50 (12) NA 37.2 (38.4) NA 56.0 (36.0) NA NA NA NA NA NA NA 30.9 (12.5)
Gold (n = 18) 72 55 (8) NA 51.6 (52.8) NA 53.0 (37.0) NA NA NA NA NA NA NA 27.6 (12.5)
Wassenberg et al. 2005 [63]
MTX-naïve
Gold (66 %)/MTX
(34 %) (n = 80)
25 53 (13) 43.0 8.6 (6.7) NA 44.5 (24.9) NA NA NA NA 11.9 (2.1) 6.0 (1.3) 6.0 (1.08) NA
Gold (59 %)/MTX
(41 %) (n = 86)
35 50 (13) 47.0 9.3 (6.6) NA 40.1 (24.6) NA NA NA NA 9.4 (1.9) 4.5 (1.2) 4.7 (0.87) NA
AZA azathioprine, CRP C-reactive protein, CSA ciclosporin A, DAS-28 disease activity score in 28 joints, DMARD disease-modifying anti-rheumatic drug, DMARD-IR patient population with moderate-to-severe RA with a
history of inadequate response to non-biologic DMARDs who are currently treated with one (other) non-biologic DMARD, ES Erosion Subscore of TSS, ESR erythrocyte sedimentation rate, gold gold salts, HAQ Health
Assessment Questionnaire, HCQ hydroxychloroquine, ITT intent to treat, JSN Joint Space Narrowing Subscore of TSS, LEF leflunomide, MTX methotrexate, NA not available, non-DMARD-IR patient population with moder-
ate-to-severe RA without a history of inadequate response to a DMARD who are currently receiving palliative care (NSAIDs, analgesics, low-dose glucocorticoids) or are being minimally treated with one
non-biologic DMARD, NSAID non-steroidal anti-inflammatory drug, RA rheumatoid arthritis, Ref reference, RF+ rheumatoid factor positive, SJC swollen joint count, SSZ sulfasalazine, TJC tender joint count,
TSS modified Total Sharp Score













biologic DMARD-naïve and non-biologic DMARD-ex-
perienced patients without an inadequate response to
any DMARD. In the identified studies, the minimally
treated DMARD-IR patients were receiving mono-
therapy with MTX, AZA, SSZ, or gold salts, with
most patients receiving MTX. In the included non-
DMARD-IR studies, DMARD treatment consisted of
MTX, SSZ, LEF, CSA, HCQ, or D-penicillamine.
Only one study was identified in which patients were
treated with NSAIDs only, but this study was not in-
cluded in the meta-analysis. For both populations,
treatment with one DMARD resulted in deterioration
of joint structure over a 2-year period as measured
with the TSS, ES, JSN, and Larsen scores. Under the
assumption that the minimal clinically important dif-
ference is about 1 % of the maximum of the possible
TSS and Larson scores, the estimated changes over a
2 year period in terms of TSS can be considered rele-
vant, in particular for the DMARD-IR population [64,
65]. Depending on the time assessed and the measure
examined, the rate of deterioration in the DARD-IR
population was about 1.5- to 2-times the rate of de-
terioration in the non-DMARD-IR population. Based
on RCT evidence, the rate of deterioration with AZA
was greater than with MTX in the DMARD-IR popu-
lation. For the non-DMARD-IR population, LEF and
MTX showed a similar progression over time.
The greater rate of deterioration observed in the
DMARD-IR population compared with the non-
DMARD-IR population makes sense, given the negative
impact a history of non-biologic-DMARD failure should
have on the effectiveness of continuation with a non-
biologic DMARD. Related underlying causes for the
difference in progression rates are possibly differences in
disease duration, rheumatoid factor status, and disease
activity.
However, it is important to note that for a subset of
the identified studies it was not clear whether the
patients were exclusively DMARD-IR. These studies
were assigned to the non-DMARD-IR group to make
sure that the DMARD-IR group was as homogenous
as possible. As such, it is possible that the defined
non-DMARD-IR population partly consisted of pa-
tients who might have a history of failed treatment
with a DMARD. This possible misclassification might
have overestimated the deterioration in this group,
and should be kept in mind when comparing the
degree of joint deterioration in DMARD-IR versus
non-DMARD-IR populations.
The relevant studies were identified by means of a sys-
tematic search of the literature and included both RCTs
and observational designs. Given the objective of the
meta-analysis, only those arms of the comparative stud-
ies were selected in which patients were treated with
NSAIDs or a single DMARD (with or without additional
NSAIDs or corticosteroid use). Although many RCTs
were included, often only one treatment arm (e.g.,
MTX-only arm from biologic trials in DMARD-IR popu-
lations) was used. As such, there was no difference in
the way evidence obtained from observational studies and
RCTs was handled. RCTs in which different single non-
biologic DMARDs were compared were included and
provided the evidence to allow comparisons between
DMARDs. Comparative analyses were only possible for
Fig. 2 Mean change from baseline in TSS in the DMARD-IR population. Data are as observed in individual studies and estimated with meta-analysis.
Solid line represents the mean estimate for a given treatment arm and the dashed lines show the corresponding 95 % credible interval. AZA: azathioprine;
DMARD-IR: patient population with moderate-to-severe rheumatoid arthritis with a history of inadequate response to disease-modifying anti-rheumatic
drugs (DMARDs) who are currently treated with one (other) non-biologic DMARD; MTX: methotrexate; TSS: modified Total Sharp Score
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AZA versus MTX and for LEF versus MTX. Although
RCTs provided comparative data for some other DMARDs,
these were not part of a connected network of RCTs and
could not, therefore, be used in the planned analyses.
Many of the MTX treatment arms comprising the
DMARD-IR population were obtained from RCTs in
which a biologic DMARD was evaluated. In the included
studies the patients in these MTX arms were not assigned
to biologic treatment within the study time horizon; only
the MTX dose could be increased in case of non-
response. Hence, the observed structural deterioration is a
reflection of the limitations of MTX in this population.
The included studies reported joint deterioration at dif-
ferent time points, with outcomes reported up to 2 years
of follow-up. With the meta-analysis models used, all the
available time points were analyzed simultaneously to esti-
mate a curve reflecting joint structural deterioration over
time. It cannot be assumed that extrapolation of these
curves beyond this 2-year period is a valid representation
of joint structure deterioration over the longer term. The
Table 3 Mean change from baseline in TSS and subscores in the DMARD-IR population as estimated with meta-analysis
Week 12 Week 24 Week 52 Week 104













DMARDs 1.14 (0.66, 1.67) >0.99 2.27 (1.31, 3.34) >0.99 4.92 (2.84, 7.23) >0.99 9.84 (5.68, 14.46) >0.99
MTXa 0.97 (0.49, 1.52) 0.99 1.95 (0.98, 3.05) 0.99 4.22 (2.13, 6.6) 0.99 8.44 (4.26, 13.21) 0.99
AZAa 2.16 (2.16, 3.04) >0.99 4.32 (2.59, 6.07) >0.99 9.35 (5.62, 13.15) >0.99 18.70 (11.24, 26.31) >0.99
Erosion Subscore
DMARDs 0.51 (0.27, 0.83) 0.99 1.02 (0.55, 1.66) 0.99 2.22 (1.19, 3.6) 0.99 4.43 (2.38, 7.21) 0.99
MTXa 0.43 (0.25, 0.69) 0.98 0.87 (0.49, 1.39) 0.98 1.88 (1.07, 3.01) 0.98 3.76 (2.14, 6.01) 0.98
AZAa 1.31 (1.31, 1.98) >0.99 2.62 (1.3, 3.96) >0.99 5.67 (2.81, 8.57) >0.99 11.35 (5.61, 17.14) >0.99
Joint Space Narrowing Subscore
DMARDs 0.36 (0.09, 0.67) 0.99 0.72 (0.18, 1.33) 0.99 1.57 (0.4, 2.89) 0.99 3.14 (0.80, 5.78) 0.90
AZA azathioprine, CrI credible interval; DMARD disease-modifying anti-rheumatic drug; DMARD-IR patient population with moderate-to-severe rheumatoid arthritis
with a history of inadequate response to non-biologic DMARDs who are currently treated with one (other) non-biologic DMARD, CFB change from
baseline; MTX methotrexate, p-value probability of joint structural deterioration relative to baseline; TSS modified Total Sharp Score
aEstimated based on comparative data only, using models for relative treatment effects (see Model 3 and 4 in Additional file 2), which allows comparative
interpretation of MTX and AZA findings
Fig. 3 Mean change from baseline in ES in the DMARD-IR population. Data are as observed in individual studies and estimated with meta-analysis. Solid
line represents the mean estimate for a given treatment arm and the dashed lines show the corresponding 95 % credible interval. AZA: azathioprine;
DMARD-IR: patient population with moderate-to-severe rheumatoid arthritis with a history of inadequate response to disease-modifying anti-rheumatic
drugs (DMARDs) who are currently treated with one (other) non-biologic DMARD; ES: Erosion Subscore; MTX: methotrexate
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vast majority of studies used the modified Sharp score to
analyze joint erosion and space narrowing. The modified
score includes feet in the radiographic assessment, in
addition to the scoring of wrists and hands as with the ori-
ginal Sharp score [6–10]. The study by Hamdy [21] used
the earlier version of the Sharp score. Despite the differ-
ences in total score, we included the study by Hamdy in
the analysis of the DMARD-IR population. We do not ex-
pect this variation in total score to be a cause of large
between-study heterogeneity in development of TSS over
time. In fact the observed TSS reported by Hamdy is very
consistent with the other studies included in that analysis
(Fig. 2).
The included studies were characterized by variability
in patient characteristics, especially among the non-
DMARD-IR studies. As a result, heterogeneity in joint
structural deterioration over time was observed. In order
to capture this heterogeneity, random-effects models were
used; however, these models do not explain the heterogen-
eity. In the future, it will be of interest to evaluate whether
Fig. 4 Mean change from baseline in JSN Subscore in the DMARD-IR population. Data are as observed in individual studies and estimated with
meta-analysis. Solid line represents the mean estimate for a given treatment arm and the dashed lines show the corresponding 95 % credible
interval. DMARD-IR: patient population with moderate-to-severe rheumatoid arthritis with a history of inadequate response to disease-modifying
anti-rheumatic drugs (DMARDs) who are currently treated with one (other) non-biologic DMARD; JSN: Joint Space Narrowing; MTX: methotrexate
Fig. 5 Mean change from baseline in TSS in the non-DMARD-IR population. Data are as observed in individual studies and estimated with
meta-analysis. Solid line represents the mean estimate for a given treatment arm and the dashed lines show the corresponding 95 % credible interval.
AZA: azathioprine; DMARD: disease-modifying anti-rheumatic drugs; DMARD-IR: patient population with moderate-to-severe rheumatoid arthritis with
a history of inadequate response to DMARDs who are currently treated with one (other) non-biologic DMARD; LEF: leflunomide; MTX: methotrexate;
SSZ: sulfasalazine; TSS: modified Total Sharp Score
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certain patient characteristics are associated with differ-
ences in joint deterioration. However, meta-regression
analysis where study level data is used to evaluate the im-
pact of patient characteristics on outcomes or treatment
effects can be prone to ecological bias [66, 67]. For such
an evaluation it is preferred to have access to patient-level
data. In this context it would be interesting to evaluate the
independent effect of steroid use, disease duration,
rheumatoid factor status, and disease activity on joint de-
terioration, for example.
Table 4 Mean change from baseline in TSS and subscores plus Larsen Score in the non-DMARD-IR population as estimated with
meta-analysis
Week 12 Week 24 Week 52 Week 104

















DMARDs 1.56 (0.79, 2.34) >0.99 2.49 (1.2, 3.79) >0.99 3.91 (1.16, 6.7) >0.99 5.13 (−1.35, 11.67) 0.94
MTXa 1.07 (0.62, 1.53) >0.99 1.76 (1, 2.57) >0.99 2.89 (1.41, 4.56) >0.99 4.15 (1.08, 7.63) >0.99
AZAa 0.73 (−0.08, 1.54) 0.96 1.34 (0.17, 2.52) 0.99 2.57 (0.86–4.41) >0.99 4.55 (1.19, 8.26) >0.99
Erosion Subscore
DMARDs 0.69 (0.31, 1.12) >0.99 1.07 (0.5, 1.67) >0.99 1.80 (0.76, 2.85) >0.99 2.93 (0.92, 5.02) >0.99
MTXa 0.64 (0.2, 1.07) >0.99 0.99 (0.32, 1.68) >0.99 1.65 (0.35, 3.05) 0.99 2.70 (0.08, 5.53) 0.98
AZAa 0.59 (0.13, 1.03) 0.99 0.88 (0.17, 1.59) 0.99 1.41 (0.05, 2.86) 0.98 2.21 (−0.53, 5.14) 0.95
Joint Space Narrowing Subscore
DMARDs 0.29 (0.17, 0.44) >0.99 0.59 (0.34, 0.88) >0.99 1.28 (0.73, 1.9) >0.99 2.55 (1.45, 3.8) >0.99
MTXa 0.26 (0.05, 0.51) 0.99 0.51 (0.1, 1.02) 0.99 1.11 (0.22, 2.2) 0.99 2.21 (0.45, 4.41) 0.99
AZAa 0.24 (0.02, 0.5) 0.98 0.48 (0.05, 1) 0.98 1.04 (0.1, 2.17) 0.98 2.08 (0.21, 4.34) 0.98
(Standardized) Larsen score
DMARDs 0.08 (0.04–0.11) >0.99 0.15 (0.08–0.22) >0.99 0.33 (0.18–0.48) >0.99 0.65 (0.36–0.96) >0.99
AZA azathioprine, CFB change from baseline, CrI credible interval, DMARD disease-modifying anti-rheumatic drug, MTX methotrexate, non-DMARD-IR patient
population with moderate-to-severe rheumatoid arthritis without a history of inadequate response to a DMARD who are currently receiving palliative care
(non-steroidal anti-inflammatory drugs, analgesics, low-dose glucocorticoids) or are being minimally treated with one non-biologic DMARD, p-value probability of joint
structural deterioration relative to baseline, TSS modified Total Sharp Score
aEstimated based on comparative data only, using models for relative treatment effects (see Model 3 and 4 in Additional file 2), which allows comparative
interpretation of MTX and AZA findings
Fig. 6 Mean change from baseline in ES in the non-DMARD-IR population. Data are as observed in individual studies and estimated with meta-analysis.
Solid line represents the mean estimate for a given treatment arm and the dashed lines show the corresponding 95 % credible interval. DMARD: disease-
modifying anti-rheumatic drugs; DMARD-IR: patient population with moderate-to-severe rheumatoid arthritis with a history of inadequate response to
DMARDs who are currently treated with one (other) non-biologic DMARD; ES: Erosion Subscore; LEF: leflunomide; MTX: methotrexate; SSZ: sulfasalazine
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There is evidence that the patients treated in biologic
trials have changed substantially over the past decade.
[68]. This is important to consider when using the find-
ings of this meta-analysis to help interpret results of new
placebo-controlled trials of biologics. In this context, a
limitation of the current analysis is that any potentially
relevant studies published after 2009 were not included.
Conclusions
Based on the currently available published evidence, it can
be concluded that minimal treatment of RA with one
non-biologic DMARD results in a high risk of deterior-
ation of joint structures among patients who have shown
an inadequate response to non-biologic DMARDs, as well
as patients that have not (yet) shown an inadequate re-
sponse. This finding is of relevance when assessing the
relative benefit of arresting joint damage with new biologic
agents based on findings of placebo-controlled trials in
which patients randomized to placebo are ‘rescued’ with
active therapy within 6 months.
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